ORIC Pharmaceuticals (ORIC) Expected to Announce Earnings on Monday

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.01. On average, analysts expect ORIC Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ORIC Pharmaceuticals Price Performance

ORIC stock traded down $0.39 during midday trading on Monday, reaching $7.64. 605,387 shares of the stock were exchanged, compared to its average volume of 1,211,307. ORIC Pharmaceuticals has a 52 week low of $6.33 and a 52 week high of $16.65. The company has a fifty day moving average price of $9.26 and a 200 day moving average price of $9.47. The stock has a market capitalization of $542.65 million, a PE ratio of -4.20 and a beta of 1.21.

Insider Buying and Selling at ORIC Pharmaceuticals

In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the sale, the chief executive officer now directly owns 778,648 shares in the company, valued at approximately $6,447,205.44. The trade was a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,286.28. Following the transaction, the chief financial officer now owns 106,764 shares in the company, valued at $884,005.92. The trade was a 7.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,361 shares of company stock valued at $350,749. 5.55% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ORIC shares. JPMorgan Chase & Co. raised their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Wedbush reiterated an "outperform" rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, January 13th. Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. HC Wainwright reaffirmed a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. Finally, Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $18.86.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.